EligibleTrials

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Recruiting · NCT07271186 · Interventional (participants receive a specific treatment) · Lead sponsor: Regeneron Pharmaceuticals

View the official record on ClinicalTrials.gov →
Type 2 diabetesChronic kidney disease

Interventions studied

ALN-ANG3EvinacumabPlacebo

What this trial is about

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Who can take part

Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

58 locations listed across 17 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.